Overview

Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis

Status:
Active, not recruiting
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
It is a randomized controlled study
Phase:
Phase 4
Details
Lead Sponsor:
Dr. Mohammad Mamun Khan
Treatments:
Methotrexate
Tofacitinib